반응식
[CH3:1][C@@:2]12[C@H:11]3[CH2:12][CH2:13][C@:14]4([CH3:25])[C:18]([C:19]5[CH:20]=[CH:21][CH:22]=[N:23][CH:24]=5)=[CH:17][CH2:16][C@H:15]4[C@@H:10]3[CH2:9][CH:8]=[C:7]1[CH2:6][C@@H:5]([OH:26])[CH2:4][CH2:3]2.[C:27](OC(=O)C)(=[O:29])[CH3:28]>C(N(CC)CC)C>[CH3:28][C:27]([O:26][C@@H:5]1[CH2:6][C:7]2[C@@:2]([CH3:1])([C@@H:11]3[C@@H:10]([CH2:9][CH:8]=2)[C@@H:15]2[CH2:16][CH:17]=[C:18]([C:19]4[CH:20]=[CH:21][CH:22]=[N:23][CH:24]=4)[C@@:14]2([CH3:25])[CH2:13][CH2:12]3)[CH2:3][CH2:4]1)=[O:29]참가 물질
실험 절차
In one embodiment of the invention, abiraterone is acetylated by using acetic anhydride in the presence of a base, preferably triethylamine, and purified in hexane and ethanol to give pure abiraterone acetate of formula (I) with an overall yield up to 43-45% from the DHEA and a high purity (up to 99.0% by HPLC). In this embodiment, charcoal and a chelating resin are advantageously added to the hexane and ethanol solution of abiraterone acetate; the reaction mixture is then filtered and the pure active ingredient is crystallized. Suitable chelating resins that can be used in the invention are immobilized resins such as complex phenol-formaldehyde based resins; the Hokuetsu brand type MA-A resin (available from Ajinomoto) being preferred.
후처리
- custompurified in hexane
출처 및 근거
- ORD 기록
- ord-15b89b14420741f79eae02e35ab6bc75
- 출처 데이터셋
- uspto-grants-2016_05
- 특허 번호
- US09353145B2
연결된 노트
불러오는 중…